1. Relationship of serum trimethylamine n-oxide (TMAO) levels with early atherosclerosis in humans
- Author
-
Ingmar Königsrainer, Xinjie Zhao, Bernd Balletshofer, Guowang Xu, Angela Lehn-Stefan, Fritz Schick, Xiaolin Wang, Elko Randrianarisoa, Jürgen Machann, Rainer Lehmann, Hans-Ulrich Häring, Norbert Stefan, Alfred Königsrainer, Andreas Fritsche, Andreas Peter, Miriam Hoene, and Silke S. Heinzmann
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Intra-Abdominal Fat ,Trimethylamine N-oxide ,Disease ,Biology ,medicine.disease_cause ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Methylamines ,Insulin resistance ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Adiposity ,Multidisciplinary ,Fatty liver ,Middle Aged ,medicine.disease ,Atherosclerosis ,Oxidative Stress ,030104 developmental biology ,Endocrinology ,chemistry ,Female ,Metabolic syndrome ,Insulin Resistance ,Oxidative stress - Abstract
Circulating trimethylamine N-Oxide (TMAO) levels predict cardiovascular disease (CVD), possibly by impacting on cholesterol metabolism and oxidative stress. Because hepatic TMAO production is regulated by insulin signalling and it is unclear whether and to what extent circulating TMAO levels associate with CVD risk, independently of insulin resistance and its important determinants fatty liver and visceral obesity, we have now addressed this question in 220 subjects who participated in the Tübingen Lifestyle Intervention Program. Visceral fat mass (r = 0.40, p 20%). We provide novel information that increased serum TMAO levels associate with increased cIMT, independently of established cardiovascular risk markers, including insulin resistance, visceral obesity and fatty liver. Furthermore, the decrease of cIMT during a lifestyle intervention may be related to the decrease of TMAO levels.
- Published
- 2016